Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14356MR)

This product GTTS-WQ14356MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Diabetic macular edema, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14356MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14569MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ15282MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ2288MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ3848MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ12880MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ2381MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ6951MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ8998MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW